Spark Investment Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Spark Investment Management’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-20,400	Closed	-$366K	–	245
2020 Q1	$366K	Sell	20,400 -20,600	-50%	-$433K	0.19%	165
2019 Q4	$972K	Buy	+41,000	New	+$996K	0.11%	250
2016 Q4	–	Sell	-40,400	Closed	-$999K	–	867
2016 Q3	$999K	Buy	+40,400	New	+$914K	0.08%	345
2016 Q1	–	Sell	-159,100	Closed	-$2.14M	–	828
2015 Q4	$2.14M	Hold	159,100	–	–	0.27%	112
2015 Q3	$2.23M	Sell	159,100 -35,800	-18%	-$666K	0.29%	98
2015 Q2	$3.31M	Buy	194,900 +28,600	+17%	+$407K	0.46%	46
2015 Q1	$2.01M	Buy	166,300 +67,800	+69%	+$641K	0.28%	103
2014 Q4	$818K	Buy	+98,500	New	+$828K	0.14%	220

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ACB

Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Spark Investment Management's SUPN Position: Q2 2020 in Review

Spark Investment Management sold out of Supernus Pharmaceuticals (SUPN) in Q2 2020, closing a stake of 20,400 shares — an estimated $366K sold.

Spark Investment Management first reported a position in SUPN in Q4 2014 and held it in 8 quarters. The position peaked at $3.31M in Q2 2015. 218 funds tracked by Wall St. Rank hold SUPN as of Q2 2020.

Spark Investment Management reported no remaining Supernus Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
Spark Investment Management sold 20,400 Supernus Pharmaceuticals shares in Q2 2020, an estimated $366K.
Spark Investment Management first reported a position in Supernus Pharmaceuticals in Q4 2014 and held it in 8 quarters.
Spark Investment Management's Supernus Pharmaceuticals position peaked at $3.31M in Q2 2015.
218 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2020.

Based on Spark Investment Management's 13F filing for Q2 2020, filed 12 Aug 2020.